Izvorni znanstveni članak
https://doi.org/10.3325/cmj.2024.65.356
Regulator of calcineurin 3 as a novel predictor of diagnosis and prognosis in pan-cancer
Yuan Liang
; Department of Gynecology, The First Hospital of Qiqihar, Qiqihar, Heilongjiang, China
Wenjuan Diao
; Department of Gynecology, Affiliated Qiqihar Hospital, Southern Medical University, Qiqihar, Heilongjiang, China
Xuefen Yang
; Department of Gynecology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China
Yue Tao
; Department of Gynecology, The First Hospital of Qiqihar, Qiqihar, Heilongjiang, China
Longnian Hong
; Department of Gynecology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China
Wenle Li
; Department of Gynecology, Affiliated Hospital of Guangdong Medical University, Zhanjiang, Guangdong, China
*
* Dopisni autor.
Sažetak
Aim To assess diagnostic and prognostic value of regulator
of calcineurin 3 (RCAN3) in various malignancies.
Methods RCAN3 expression levels were assessed across
pan-cancer data sets including various molecular and immune subtypes. Receiver operating characteristic (ROC)
and Kaplan-Meier curves were employed to determine
the diagnostic and prognostic value of RCAN3 in pan-cancer, respectively. Enrichment analyses were used to identify RCAN3-associated terms and pathways. A special focus was placed on cervical squamous cell carcinoma and
endocervical adenocarcinoma cervical cancer (CESC); we
assessed the prognostic value of RCAN expression within
distinct clinical subgroups and its effect on m6A modifications and immune infiltration.
Results RCAN3 expression varied not only in different
cancer types but also in different molecular and immune
subtypes of cancers. RCAN3 displayed high accuracy in diagnosing and predicting cancers, and RCAN3 expression
level was associated with the prognosis of certain cancers.
CESC patients with a high RCAN3 level had a worse overall survival, disease-specific survival, and progression-free
interval. RCAN3 expression was related to multiple m6A
modifier genes and immune cells.
Conclusion In general, RCAN3 can serve as a novel biomarker for the diagnosis and prognosis in pan-cancer, especially in CESC. It may represent a promising molecular
target for developing new treatments. However, our analysis is limited to bioinformatic predictions, and further biological experiments are necessary to verify our results
Ključne riječi
Hrčak ID:
336469
URI
Datum izdavanja:
20.8.2024.
Posjeta: 23 *